Nuh Atas

Nuh Atas

Auto-generated profile, based on publicly available information

Nuh Atas

Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
NANuh Atas
Nuh Atas
BABerkan Armağan
Berkan Armağan
EBErdal Bodakçi
Erdal Bodakçi
HSHasan Satis
Hasan Satis
ASAlper Sari
Alper Sari
ATABDURRAHMAN TUFAN
ABDURRAHMAN TUFAN

1 November 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
ULUlf Lindström
Ulf Lindström
DGDaniela Di Giuseppe
Daniela Di Giuseppe
BDBénédicte Delcoigne
Bénédicte Delcoigne
BGBente Glintborg
Bente Glintborg
Burkhard MöllerBurkhard Möller
Burkhard Möller
MNMichael J Nissen
Michael J Nissen
Background Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods Patients with PsA from 13 European countries who initiated a first TNFi in 2006–2017 were included. Country-specific comparisons of 1 year TNFi retention were performed by csDMARD comedication status, together with HRs for TNFi discontinuation (comedication vs monotherapy), adjusted for age, sex, calendar year, disease duration and Disease Activity Score with 28 joints (DAS28). Adjusted ORs of clinical remission (based on DAS28) at 12 months were calculated. Between-country heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Secondary analyses stratified according to TNFi subtype (adalimumab/infliximab/etanercept) and restricted to methotrexate as comedication were performed. Results In total, 15 332 patients were included (62% comedication, 38% monotherapy). TNFi retention varied across countries, with significant heterogeneity precluding a combined estimate. Comedication was associated with better remission rates, pooled OR 1.25 (1.12–1.41). Methotrexate comedication was associated with improved remission for adalimumab (OR 1.45 (1.23–1.72)) and infliximab (OR 1.55 (1.21–1.98)) and improved retention for infliximab. No effect of comedication was demonstrated for etanercept. Conclusion This large observational study suggests that, as used in clinical practice, csDMARD and TNFi comedication are associated with improved remission rates, and specifically, comedication with methotrexate increases remission rates for both adalimumab and infliximab.

10 August 2020 in Rheumatology
Verified
Journal Article
Closed access
HBHakan Babaoglu
Hakan Babaoglu
BABerkan Armagan
Berkan Armagan
EBErdal Bodakci
Erdal Bodakci
HSHasan Satis
Hasan Satis
NANuh Atas
Nuh Atas
ATAbdurrahman Tufan
Abdurrahman Tufan
Objective: Persistent inflammation is an insidious and less studied feature of FMF. We investigated clinical determinants of persistent inflammation and its associations with individual damage items. Methods: This is a cross-sectional analysis of 917 FMF patients, who fulfilled the Tel Hashomer criteria and had at least 6 months’ follow-up. Patients were stratified based on whether they had persistent inflammation. We used logistic regression analysis to investigate independent predictors of persistent inflammation and the associated individual damage items. Results: One hundred and forty-two (15%) patients had persistent inflammation. Active FMF (54%) was the most prominent reason for the persistent inflammation. Spondylarthritis (16%), other inflammatory arthritis (8%) and IBD (2%) were other frequent reasons. Male gender, history of exertional leg pain, inflammatory comorbidities, M694V homozygosity, colchicine resistance, lower education levels and musculoskeletal attack dominance were found to be the independent predictors of persistent inflammation. Earlier disease onset led to a tendency towards persistent inflammation. Patients with persistent inflammation were more likely to suffer damage. There is an increased risk of developing proteinuria, amyloidosis and renal insufficiency. Conclusion: We identified, for the first time, the predictors of persistent inflammation in adult FMF patients and related individual damage items of the Autoinflammatory Disease Damage Index. Persistent inflammation is insidious and one of the chief causes of damage; therefore, especially patients with these predictors should be followed up more closely. If detected, underlying inflammatory comorbidities should be assessed meticulously as early detection and proper treatment strategies may favourably impact the natural history of the disease.

6 October 2021 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
NANuh Atas
Nuh Atas
GEGulsah Atbiner Eroglu
Gulsah Atbiner Eroglu
HSHulya Nur Sodan
Hulya Nur Sodan
BOBeyza Olcay Ozturk
Beyza Olcay Ozturk
HBHakan Babaoglu
Hakan Babaoglu
ATAbdurrahman Tufan
Abdurrahman Tufan
Full Papers; Authors: N. Atas, G.A. Eroglu, H.N. Sodan, B.O. Ozturk, H. Babaoglu, H. Satis, H. Karadeniz, A.A. Guler, R.B. Salman, B. Goker, M.A. Ozturk, S. Haznedaroglu, A. Tufan

22 October 2020 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
SYSongul Baglan Yentur
Songul Baglan Yentur
NANuh Ataş
Nuh Ataş
MÖMehmet Akif Öztürk
Mehmet Akif Öztürk
DODeran Oskay
Deran Oskay

7 December 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
HKHazan Karadeniz
Hazan Karadeniz
AGAslihan Avanoglu Guler
Aslihan Avanoglu Guler
NANuh Atas
Nuh Atas
HSHasan Satış
Hasan Satış
RSReyhan Bilici Salman
Reyhan Bilici Salman
ATABDURRAHMAN TUFAN
ABDURRAHMAN TUFAN